- Title
- LB010/#1590 A phase 2 randomized dose optimization trial of gotistobart, a PH-sensitive anti-CTLA-4, in combination with pembrolizumab in platinum-resistant ovarian cancer (PROC, preserve-004/GOG-3081; NCT05446298)
- Creators
- Joyce Barlin - Women’s Cancer Care Associates, Albany, United States of AmericaPeter Lim - Center of Hope, Gynecologic Oncology, Reno, United States of AmericaJessica Thomes Pepin - Minnesota OncologyElizabeth Hopp - Medical College of WisconsinNoelle Cloven - Texas Oncology, Austin, United States of AmericaHelen Eshed - Texas Oncology, Austin, United States of AmericaDestin Black - Willis-Knighton Cancer CenterHope Cottrill - Central Baptist HospitalLauren Hand - New England Baptist HospitalDavid O’Malley - The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research InstituteLinus Chuang - Danbury HospitalMichael Chisamore - MerckJoan Durbin - OncoC4 Inc, Rockville, United States of AmericaPan Zheng - OncoC4 Inc, Rockville, United States of AmericaYang Liu - OncoC4 Inc, Rockville, United States of AmericaSvetlana Shpyro - BioNTech SE, Mainz, GermanyBradley Monk - Florida Cancer Specialists, West Palm Beach, United States of America
- Publication Details
- International journal of gynecological cancer, Vol.34, pp.A6-A8
- Publisher
- Elsevier Inc
- Identifiers
- 991006133436302656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article
Journal article
LB010/#1590 A phase 2 randomized dose optimization trial of gotistobart, a PH-sensitive anti-CTLA-4, in combination with pembrolizumab in platinum-resistant ovarian cancer (PROC, preserve-004/GOG-3081; NCT05446298)
International journal of gynecological cancer, Vol.34, pp.A6-A8
10/2024
Metrics
1 Record Views